anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

204,241-204,300 of 319,975

filter-aware
07
The slide features a thumbnail of a scientific poster titled 'Breaking barriers to access intracellular targets with T-cell engagers'.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a dark overlay on a photo of people working, with a prominent callout box for the key achievement.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · Evidence & Proof1 hit
09
The slide uses a dark overlay on a professional photo to emphasize the text.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · Evidence & Proof1 hit
10
Uses a three-pillar strategic framework for capital allocation.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
11
AbCellera | Results Presentation Deck | 18 slidesAbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
12
The slide uses a combination of big numbers and stacked bar charts to visualize cumulative growth over time.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
13
The slide highlights a new undisclosed molecule in Phase 1.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
14
The chart uses a broken axis for the Q1 2022 bar to accommodate the large royalty component.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
15
The slide uses a waterfall-style annotation to show the absolute dollar increase between the two periods.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
16
The slide uses a side-by-side bar chart comparison for three metrics: Net Earnings, Basic EPS, and Diluted EPS.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
17
The chart illustrates the bridge between two balance sheet dates using cash flow categories.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
18
AbCellera | Results Presentation Deck | 18 slidesAbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations 1 hit
01
Slide 1
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Setup1 hit
02
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Setup1 hit
03
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · SetupLoop · Logic Chain1 hit
04
The slide uses a structured table-like layout to compare two key metrics across three business units.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
05
The chart shows a multi-year trend of in-store sampling events, with a specific callout for +27% YOY growth.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
06
Includes a visual representation of debt maturity and a callout regarding interest rate hedging.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
07
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
08
Includes footnotes (1) through (9) referenced in the table rows.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
09
The slide presents two separate tables for Sales and Marketing segments, detailing various add-backs to operating income.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
10
Includes footnotes referencing specific adjustments (10-13).Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
11
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
12
This slide provides the definitions for the numbered references used in the preceding non-GAAP reconciliation tables.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
13
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Reflection1 hit
01
Slide 1
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
04
The slide uses a Gantt-style chart to represent clinical trial progress.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
05
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
06
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
07
Includes testimonials from KOLs to emphasize the difficulty of patient compliance.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
08
The slide uses a pie chart to segment patients and a timeline/number line to show age of diagnosis, followed by key metrics on clinical complications.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
09
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach1 hit
11
The chart displays efficacy data for a drug candidate (pegtarviliase) across different dosage cohorts.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
ADA stands for Anti-Drug Antibodies.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a timeline-based progression of symptoms to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
Includes box plots for arginine levels and bar charts for patient normalization rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
19
The slide uses a heatmap to display individual patient outcomes across four metrics (pArg, GMFM-E, 2MWT, GMFM-D).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
20
The slide presents clinical trial safety data comparing Pegzilarginase to a placebo group.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
22
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
23
The slide presents a standard quarterly financial comparison (P&L summary) and balance sheet highlights.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Before After1 hit
26
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
27
The slide includes experimental design details and statistical significance markers (p < 0.05).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
28
Includes survival curve (Kaplan-Meier) and pharmacodynamic response (tHcy levels over time).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
29
Includes histological images of liver tissue and a dot plot showing bone mineral density (BMD) improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
30
The table displays mean/SD, range, and counts/percentages for Pegzilarginase (n=21), Placebo (n=11), and Overall (N=32).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
31
Data includes Plasma Arginine, GMFCS level, GMFM-E, and 2MWT metrics.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
32
The chart is a box-and-whisker plot showing longitudinal data from baseline through 56 weeks.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
34
Includes a study design timeline at the bottom right and MCID reference lines on the GMFM-E chart.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
35
Slide details GMFCS classification levels and GMFM/Timed Walk Test methodologies.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit